Compare Becton Dickinson and Co (BDX) vs Lithium Americas Corp (LAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Lithium Americas Corp — how do they compare? Becton Dickinson and Co trades at $155 (market cap $41.51B), while Lithium Americas Corp trades at $3.11 (market cap $1.11B). The key difference: Becton Dickinson and Co is far larger — about 37.4× Lithium Americas Corp's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.
| BDX | LAC | |
|---|---|---|
Market Cap | $41.51B | $1.11B |
Sector | Health | Basic Materials |
52-Week High | $185.39 | $10.05 |
52-Week Low | $135.49 | $2.55 |
Enterprise Value | $57.97B | $1.22B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Lithium Americas (LAC) trades at $3.14, down 5.42% on the day, reflecting ongoing market pressure despite recent earnings beats. The stock shows mixed signals with bearish technical indicators but bullish oscillators suggesting potential oversold conditions. Fundamentally, the company remains in development phase with negative profitability metrics (ROE -11.35%, net loss $122M in 2025) but maintains analyst support for its Thacker Pass lithium project development.
LAC presents a high-risk, high-reward opportunity with significant execution risk on its capital-intensive lithium project. While analyst consensus targets $6.25 (99% upside), investors face dilution risk from ongoing financing needs and operational challenges. The stock's appeal hinges on successful project development and lithium market recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
